Why has the NMC Health share price crashed?

Shares in NMC health have been doing poorly since mid-2018 but took a turn for the worse in December last year. Things are only getting worse.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Things looked so very different a little over six months ago for investors in NMC Health (LSE: NMC).

After being listed on the London Stock Exchange in 2012, NMC’s share price went sideways, then started to rise through 2013 and 2014. The price of NMC shares doubled in 2015, then again in 2016 and 2017, rising by 644% over that period in total. At the same time revenues had increased, as had profits and dividends.

The gains continued into 2018, all the way into mid-August. A half-year report released on the 20th of that month showed revenue was still robust at 20% but had fallen from the 34% seen a year previously. The spouse of NMC’s company secretary also disposed of a chunk of shares in August 2018.

NMC management issued upward revisions to forward guidance in October 2018, but NMC’s share price ended 2018 below where it started it.

Muddying the waters

The NMC share price continued its slide in 2019. A full-year report showing that revenues and profits grew by 28.3% and 20.4% respectively did little to arrest the decline.

Things took a turn for the worse in December 2019, when Muddy Waters Capital announced it was shorting NMC shares, and told the world why. In short, Muddy Waters accused NMC of significant accounting fraud and corporate governance failings. The NMC share price has fallen by close to 70% from 2,585p before Muddy’s report to 790p today.

NMC responded by rubbishing the claims made by Muddy but also announced an independent review to address all the allegations. Non-executive directors of NMC are set to oversee the independent review. One of these was already noted by Muddy to be a former partner at NMC’s auditors. In January NMC announced that a former FBI director’s investigation firm would conduct the independent review.

Who guards the guards?

This week NMC announced that B.R. Shetty, the founder and chair of NMC, and his advisers were carrying out their own review. Shetty believes he may have incorrectly reported his shareholdings in NMC. His associated family members and their holdings companies’ interests in NMC’s shares are also under review, as are the interests of other directors of NMC.

Shetty’s name appeared numerous times in Muddy’s report and he also controls fintech firm Finablr, which owns Travelex. Finablr’s share price has also tanked since December, and the boards of NMC and Finablr share members. Shetty has been asked to absent himself from board meetings at NMC.

The fact that shareholdings could be stated incorrectly is evidence that fact-checking at the company is weak.

Two of NMC’s largest shareholders sold up large amounts of stock this week, and another one also reduced its stake. Also, this week potential takeover offers from Kravis Roberts & Co. L.P. and GK Investment Holding Group for NMC were disclosed. This latest event has brought some support for NMC’s beleaguered share price.

Getting taken over and going private may be for the best. NMC has lost credibility with public markets and investors. I do not believe announcing impressive full-year 2019 results or the independent review exonerating NMC of Muddy’s allegations will restore much faith.

NMC was exciting because it was both an income and a growth stock. Right now, however, I would avoid NMC like the plague.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

James J. McCombie has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »